- Published on
Infectious Disease and Microbiology – Ehrlichiosis and Anaplasmosis
Ehrlichiosis and anaplasmosis are systemic infections caused by obligate intracellular bacteria belonging to the family Anaplasmataceae, which includes the genera Ehrlichia, Anaplasma, Neorickettsia, and Wolbachia. These organisms primarily infect humans through tick bites, especially during the summer months when tick activity is highest. They target cells of the reticuloendothelial system, particularly monocytes and granulocytes, leading to a wide range of clinical manifestations. In immunocompetent individuals, the disease is often mild to moderate, presenting with nonspecific symptoms such as fever, malaise, headache, myalgias, nausea, and vomiting. However, in immunocompromised patients, including those with AIDS or on corticosteroid therapy, infections may become severe, with central nervous system involvement, multiple organ dysfunction, and even death.
Epidemiologically, ehrlichiosis and anaplasmosis are primarily reported in the United States but also occur worldwide. Human monocytic ehrlichiosis (HME), caused by Ehrlichia chaffeensis, is transmitted mainly by the tick Amblyomma americanum, particularly in the southeastern and south-central US. Human granulocytic anaplasmosis (HGA), caused by Anaplasma phagocytophilum, is transmitted by Ixodes scapularis, with most cases reported in regions such as Wisconsin, Minnesota, New England, New Jersey, and New York. Cases are also reported in parts of Europe. Subclinical infections are common, and many cases are underdiagnosed. Coinfections with other tick-borne pathogens, such as Babesia microti and Borrelia burgdorferi, may occur due to shared vectors.
Risk factors include exposure to tick-infested environments, outdoor activities in endemic areas, and immunosuppression. Prevention focuses on avoiding tick bites by wearing protective clothing, using insect repellents containing DEET, and performing thorough body checks after potential exposure. Prompt removal of ticks is essential to reduce transmission risk.
The pathophysiology involves bacterial invasion of host immune cells, where the organisms reside within membrane-bound vacuoles. Ehrlichia chaffeensis primarily infects macrophages, while Anaplasma phagocytophilum targets granulocytes. These infections lead to hematologic abnormalities such as leukopenia and thrombocytopenia, as well as systemic inflammation. If untreated, the disease can progress to severe multisystem involvement.
Clinically, symptoms usually develop about 7 days after a tick bite. Patients present with fever, malaise, headache, myalgias, nausea, and sometimes rash, which may be maculopapular or hemorrhagic. Lymphadenopathy and hepatosplenomegaly may occur. Severe cases can progress to septic shock, acute respiratory distress syndrome, and neurological complications such as seizures or coma. Human granulocytic anaplasmosis presents similarly but may lack rash unless there is coinfection with other tick-borne diseases.
Diagnosis is based on clinical suspicion supported by laboratory findings. Common laboratory abnormalities include leukopenia, thrombocytopenia, anemia, and elevated liver enzymes. Serologic testing using indirect immunofluorescence is considered the gold standard but may be negative early in the disease. Polymerase chain reaction (PCR) testing offers higher sensitivity during acute infection but requires specialized laboratories. Blood smear examination has low sensitivity. Imaging such as chest X-ray may show findings consistent with acute respiratory distress syndrome in severe cases.
The differential diagnosis includes other infectious and noninfectious conditions such as endocarditis, septicemia, vasculitis, thrombotic thrombocytopenic purpura, and other tick-borne illnesses including tularemia, babesiosis, Lyme disease, Rocky Mountain spotted fever, and murine typhus.
Treatment should be initiated promptly when the disease is suspected. Doxycycline is the first-line therapy and is effective for both ehrlichiosis and anaplasmosis, typically resulting in clinical improvement within 24–48 hours. Treatment duration is usually 7–14 days. In cases where doxycycline cannot be used, such as pregnancy, rifampin may be considered. Chloramphenicol has been used but is less reliable and may not be effective in all cases.
Follow-up is important to ensure clinical improvement, as lack of response within 48 hours should prompt reconsideration of the diagnosis. Persistent infection has been reported despite treatment, and expert consultation may be necessary in complicated cases.
Complications can be severe, particularly if untreated. These include respiratory failure, neurological involvement, acute renal failure, gastrointestinal hemorrhage, and death. Hospitalization is common, with a significant proportion of patients developing severe disease. Mortality rates are estimated at 2–5%, with higher risk in elderly and immunocompromised individuals.
0 Comments
